Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA. Durand-Réville TF, et al. Among authors: moussa sh. Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104. Nat Microbiol. 2017. PMID: 28665414
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.
McLeod SM, Shapiro AB, Moussa SH, Johnstone M, McLaughlin RE, de Jonge BLM, Miller AA. McLeod SM, et al. Among authors: moussa sh. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01576-17. doi: 10.1128/AAC.01576-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29133555 Free PMC article.
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent.
Barnes MD, Kumar V, Bethel CR, Moussa SH, O'Donnell J, Rutter JD, Good CE, Hujer KM, Hujer AM, Marshall SH, Kreiswirth BN, Richter SS, Rather PN, Jacobs MR, Papp-Wallace KM, van den Akker F, Bonomo RA. Barnes MD, et al. Among authors: moussa sh. mBio. 2019 Mar 12;10(2):e00159-19. doi: 10.1128/mBio.00159-19. mBio. 2019. PMID: 30862744 Free PMC article.
In Vitro Characterization of ETX1317, a Broad-Spectrum β-Lactamase Inhibitor That Restores and Enhances β-Lactam Activity against Multi-Drug-Resistant Enterobacteriales, Including Carbapenem-Resistant Strains.
Miller AA, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Tommasi R, Mueller JP. Miller AA, et al. Among authors: moussa sh. ACS Infect Dis. 2020 Jun 12;6(6):1389-1397. doi: 10.1021/acsinfecdis.0c00020. Epub 2020 May 14. ACS Infect Dis. 2020. PMID: 32255609 Free article.
N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
Furuya T, Shapiro AB, Comita-Prevoir J, Kuenstner EJ, Zhang J, Ribe SD, Chen A, Hines D, Moussa SH, Carter NM, Sylvester MA, Romero JAC, Vega CV, Sacco MD, Chen Y, O'Donnell JP, Durand-Reville TF, Miller AA, Tommasi RA. Furuya T, et al. Among authors: moussa sh. Bioorg Med Chem. 2020 Dec 15;28(24):115826. doi: 10.1016/j.bmc.2020.115826. Epub 2020 Oct 28. Bioorg Med Chem. 2020. PMID: 33160146
45 results